Stay updated on TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Sign up to get notified when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.

Latest updates to the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study record page now displays a 403 Forbidden error, blocking access to its content. Users can no longer view the study details, eligibility criteria, contacts, or locations from that page.SummaryDifference19%

- Check15 days agoChange DetectedThe contact information label was standardized from 'Find Contact Information' to 'Find contact information', and the page revision tag was updated from v3.6.6 to v3.7.0, signaling a small UI/text update and version bump.SummaryDifference0.1%

- Check29 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6. This indicates a new version of the page has been published.SummaryDifference0.2%

- Check36 days agoChange DetectedNo textual changes are documented in the provided data; the page content remains as described in the current study record. The study details, including design, endpoints, and eligibility criteria, remain centered on the TNT trial and its locations.SummaryDifference0.1%

- Check50 days agoChange DetectedThe revision label on the page was updated from Revision: v3.6.4 to Revision: v3.6.5. This signals a new version of the page content.SummaryDifference0.2%

- Check58 days agoChange DetectedNo additions or deletions are present in the change data, so the study page content remains unchanged.SummaryDifference0.1%

Stay in the know with updates to TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Enter your email address, and we'll notify you when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.